# US 2013/0251670 A1 · Treatment of Macular Edema Utilizing Stem Cell and Conditioned Media Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0251670 A1
- Document ID: US20130251670A1
- Status: Published application
- Kind: A1
- Application number: 13/615,043
- Filed: 2012-09-13
- Published: 2013-09-26
- Earliest claimed: 2011-09-13
- Assignees: Aidan Products, Inc
- Inventors: Neil H. Riordan; Jorge Paz Rodriguez
- Web page: https://patentgrep.com/patent/US20130251670A1

## CPC

- A61K 35/51: Umbilical cord; Umbilical cord blood; Umbilical stem cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Described are methods of treating macular edema, as well as other complications of ocular inflammation, through the administration of various stem cell populations and conditioned media thereof. In one embodiment a patient suffering from macular edema is administered an intramuscular dose of media conditioned by placental mesenchymal stem cells at a sufficient concentration and frequency to elicit a reduction in ocular inflammation. Other embodiments of the invention teach intra-ocular, intravenous, sublingual, and oral means of delivery conditioned media from various stem cell populations that has been optimized for anti-inflammatory, regenerative, and immune modulatory properties.

## Claims

### Claim 1

A method of treating an ocular disorder comprising the steps of: a) extracting a cell possessing regenerative activity; b) contacting said cell with a liquid media; c) extracting liquid media; and d) administering said media to a patient in need thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein said ocular disorder is selected from a group of disorders comprising: a) macular degeneration; b) diabetic retinopathy; c) dry eye syndrome; and d) macular edema.

### Claim 3 (depends on 1)

The method of claim 1, wherein said ocular disorder is selected from a group comprising of: dry disorders of cornea and conjunctiva; b) disorders of the keratoconjunctival epithelium; c) syndrome with decrease in tear secretion; d) xerophthalmia; e) dry eye due to aging; f) ophthalmopathy in Stevens-Johnson syndrome; g) ophthalmopathy in Sjogren's syndrome; h) keratoconjunctival ulcer; i) dryness in wearing of contact lens; and j) surgery/lasix associated eye dryness.

### Claim 4 (depends on 1, 3)

The method of claim 3, wherein said ocular disorder is treated by topically applying said liquid media extracted from claim 1.

### Claim 5 (depends on 1)

The method of claim 1, wherein said cell possessing regenerative activity is selected from a group of cells comprising of: embryonic stem cells, cord blood stem cells, placental stem cells, bone marrow stem cells, amniotic fluid stem cells, neuronal stem cells, circulating peripheral blood stem cells, mesenchymal stem cells, germinal stem cells, adipose tissue derived stem cells, exfoliated teeth derived stem cells, hair follicle stem cells, dermal stem cells, parthenogenically derived stem cells, reprogrammed stem cells and side population stem cells.

### Claim 6 (depends on 5)

The method of claim 5, wherein said embryonic stem cells are totipotent and express one or more antigens selected from a group consisting of: stage-specific embryonic antigens (SSEA) 3, SSEA 4, Tra-1-60 and Tra-1-81, Oct-3/4, Cripto, gastrin-releasing peptide (GRP) receptor, podocalyxin-like protein (PODXL), Rex-1, GCTM-2, Nanog, and human telomerase reverse transcriptase (hTERT).

### Claim 7 (depends on 5)

The method of claim 5, wherein said cord blood stem cells are multipotent and capable of differentiating into endothelial, smooth muscle, and neuronal cells.

### Claim 8 (depends on 7)

The method of claim 7, wherein said cord blood stem cells are identified based on expression of one or more antigens selected from a group comprising: SSEA-3, SSEA-4, CD9, CD34, c-kit, OCT-4, Nanog, and CXCR-4

### Claim 9 (depends on 8)

The method of claim 8, wherein said cord blood stem cells do not express one or more markers selected from a group comprising of: CD3, CD34, CD45, and CD11b.

### Claim 10 (depends on 13)

The method of claim 13, wherein said placental stem cells are isolated from the placental structure.

### Claim 11 (depends on 10)

The method of claim 10, wherein said placental stem cells are identified based on expression of one or more antigens selected from a group comprising: Oct-4, Rex-1, CD9, CD13, CD29, CD44, CD166, CD90, CD105, SH-3, SH-4, TRA-1-60, TRA-1-81, SSEA-4 and Sox-2.

### Claim 12 (depends on 5)

The method of claim 5, wherein said bone marrow stem cells comprise of bone marrow mononuclear cells.

### Claim 13 (depends on 12)

The method of claim 12, wherein said bone marrow stem cells are selected based on the ability to differentiate into one or more of the following cell types: endothelial cells, smooth muscle cells, and neuronal cells.

### Claim 14 (depends on 13)

The method of claim 13, wherein said bone marrow stem cells are selected based on expression of one or more of the following antigens: CD34, c-kit, flk-1, Stro-1, CD105, CD73, CD31, CD146, vascular endothelial-cadherin, CD133 and CXCR-4.

### Claim 15 (depends on 10)

The method of claim 10, wherein said placental stem cells are isolated from the Wharton's Jelly.

### Claim 16 (depends on 10)

The method of claim 10, wherein said placental stem cells are mesenchymal in morphology.

### Claim 17 (depends on 16)

The method of claim 16, wherein said placental cell expresses one or more cytokines associated with a regenerative activities.

### Claim 18 (depends on 17)

The method of claim 17, wherein said cytokines associated with regenerative activity as selected from a group comprising of CS-6, IL-6, IL-8, SDF-1, CXCL5, VEGF, CXCL6, COL4A4, MMP13, CYP7B1, ADAMDEC1, SLC6A1, CXCL1, PF4V1, CXCL3, CH25H, SFRP2, MMP1, DARC, HCK, bFGF, ERC2, CLIC6, and BCL8 in a 75% confluent culture.

### Claim 19 (depends on 18)

The method of claim 18, wherein said placental stem cells exhibit expression of about 0.0-2,200.0 pg/ml of each of the one or more cytokines in a 75% confluent culture.

### Claim 20 (depends on 18)

The method of claim 18, wherein said placental cell exhibits expression of between 200.0-1900.0 pg/ml of IL-6 in a 75% confluent culture.

### Claim 21 (depends on 18)

The method of claim 18, wherein, said cell expresses between 350.0-2,000.0 pg/ml of bFGF in a 75% confluent culture.

### Claim 22 (depends on 18)

The method of claim 18, wherein said cell expresses between 500.0-2,500.0 pg/ml of VEGF in a 75% confluent culture.

### Claim 23 (depends on 18)

The method of claim 18, wherein said cell expresses between 140.0-1,500.0 pg/ml of SDF-1 in a 75% confluent culture.

### Claim 24 (depends on 1)

The method of claim 1, wherein said cell is an immortalized cell with regenerative activity.

### Claim 25 (depends on 24)

The method of claim 24, wherein said cell population is immortalized by means selected from a group comprising of; a) transfection with an oncogene; b) transfection telomerase; and c) transfection with a combination of an oncogene and telomerase.

### Claim 26 (depends on 25)

The method of claim 25, wherein said cell population is immortalized by means of transfection with an oncogene selected from a group of oncogenes comprising of: a) abl; b) Af4/hrx; c) akt-2; d) alk; e) alk/npm; f) aml1; g) aml1/mtg8; h) bcl-2, 3, 6; i) bcr/abl; j) c-myc; k) dbl; l) dek/can; m) E2A/pbx1; n) egfr; o) enl/hrx; p) erg/TLS; q) erbB; r) erbB-2; s) ets-1; t) ews/fli-1; u) fms; v) fos; w) fps; x) gli; y) gsp; z) gsp; aa) HER2/new; ab) hox11; ac) hst; ad) IL-3; ae) int-2; af) jun; ag) kit; ah) KS3; ai) K-sam; aj) Lbc; ak) lck; al) Imol, Imo-2; am) L-myc; an) lyl-1; ao) lyt-10; ap) lyt-10/C alpha 1; aq) mas; ar) mdm-2; as) mll; at) mos; au) mtg8/am11; av) myb; aw) MYH11; ax) new; ay) N-myc; az) ost; ba) pax-5; bb) pbx1/E2a; bc) pim-1; bd) PRAD-1; be) raf; bf) RAR/PML; bg) Ras H, K, N; bh) rel/nrg; bi) ret; bj) rhom1, rhom2; bk) ros; bl) ski; bm) sis; bn) set/can; bo) src; bp) Tal1, tal2; bq) tan-1; br) Tiam1; bs) TSC2; and bt) trk.

### Claim 27 (depends on 5)

The method of claim 5, wherein said adipose stem cell expresses markers selected from a group comprising of: CD13, CD29, CD44, CD63, CD73, CD90, CD166, Aldehyde dehydrogenase (ALDH), and ABCG2.

### Claim 28 (depends on 26)

The method of claim 26, wherein said adipose tissue derived stem cells are a population of purified mononuclear cells extracted from adipose tissue capable of proliferating in culture for more than 1 month.

### Claim 29 (depends on 5)

The method of claim 5, wherein said side population cells are derived from tissues such as pancreatic tissue, liver tissue, smooth muscle tissue, striated muscle tissue, cardiac muscle tissue, bone tissue, bone marrow tissue, bone spongy tissue, cartilage tissue, liver tissue, pancreas tissue, pancreatic ductal tissue, spleen tissue, thymus tissue, Peyer's patch tissue, lymph nodes tissue, thyroid tissue, epidermis tissue, dermis tissue, subcutaneous tissue, heart tissue, lung tissue, vascular tissue, endothelial tissue, blood cells, bladder tissue, kidney tissue, digestive tract tissue, esophagus tissue, stomach tissue, small intestine tissue, large intestine tissue, adipose tissue, uterus tissue, eye tissue, lung tissue, testicular tissue, ovarian tissue, prostate tissue, connective tissue, endocrine tissue, and mesentery tissue.

### Claim 30 (depends on 1)

The method of claim 1, wherein said liquid media is selected from a group of media useful for maintaining cell viability in culture consisting of a group comprising of: a) alpha MEM; b) DMEM; c) RPMI; d) Opti-MEM; e) IMEM; and f) AIM-V media.

### Claim 31 (depends on 1)

The method of claim 1, wherein said cells are expanded in liquid media containing fetal calf serum and subsequently cultured in media substantially lacking said fetal calf serum, with said culture lacking fetal calf serum used for production of a therapeutic product.

### Claim 32 (depends on 1)

The method of claim 1, wherein said contact between said cell and liquid media is between 1 minute to 96 hours.

### Claim 33 (depends on 1)

The method of claim 1, wherein said contact between said cell and liquid media is between 12 hours to 72 hours.

### Claim 34 (depends on 1)

The method of claim 1, wherein said contact between said cell and liquid media is between 24 hours to 48 hours.

### Claim 35 (depends on 1)

The method of claim 1, wherein said contact between said cell and liquid media is approximately 24 hours.

### Claim 36 (depends on 1)

The method of claim 1, wherein said contact between said cell and liquid media is selected for a timepoint in which optimal secretion of therapeutic factors occurs in said liquid media.

### Claim 37 (depends on 1)

The method of claim 1, wherein said liquid media is administered via a route of administration selected from: subcutaneously, intramuscularly, intra-ocularly, intravenously, topically, sublingually, or intralymphatically.

### Claim 38 (depends on 1)

The method of claim 1, wherein said liquid media is administered intramuscularly.

### Claim 39 (depends on 1)

The method of claim 1, wherein said liquid media is concentrated and desalted prior to administration.
